Contineum Therapeutics, Inc. (CTNM)

NASDAQ: CTNM · IEX Real-Time Price · USD
15.50
-0.42 (-2.64%)
Apr 12, 2024, 4:30 PM EDT - Market closed
-2.64%
Market Cap 389.53M
Revenue (ttm) 50.00M
Net Income (ttm) 3.15M
Shares Out 25.13M
EPS (ttm) 0.13
PE Ratio 123.82
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 103,172
Open 15.45
Previous Close 15.92
Day's Range 14.32 - 15.70
52-Week Range 13.90 - 15.99
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About CTNM

Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple scl... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 5, 2024
Employees 31
Stock Exchange NASDAQ
Ticker Symbol CTNM
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Contineum Therapeutics Announces Pricing of Initial Public Offering

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule ther...

7 days ago - GlobeNewsWire

Neuroscience and inflammation biotech Contineum Therapeutics files for a $150 million IPO

Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for NI&I indications, filed on Friday with the SEC to raise up to $150 million in an initial public offering.

4 weeks ago - Renaissance Capital

Contineum Therapeutics IPO Registration Document (S-1)

Contineum Therapeutics has filed to go public with an IPO on the NASDAQ.

4 weeks ago - SEC